RFA-ES-21-006: CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 20, 2023.
From the official notice on Grants.gov, last changed June 25, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNEI, NIEHS
- Median yearly award$462,958
- Typical project length3 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-ES-21-006 were run by National Eye Institute (NEI, 13 projects) and National Institute of Environmental Health Sciences (NIEHS, 11 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-ES-21-006 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-ES-24-005 | June 7, 2024 | Closed May 23, 2025 | Closed |
Key dates
| Posted | June 25, 2021 |
|---|---|
| Deadline | September 20, 2023 |
| Archived by Grants.gov | October 26, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the money in the 3 programs behind this notice (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the eyes and lungs. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP).
Funded under RFA-ES-21-006 so far
NIH funded 24 projects under RFA-ES-21-006 in fiscal 2022 to 2026, at 18 institutions. The median yearly award was $462,958.
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Vision Research grants before
From fiscal 2021 to 2025, Vision Research (93.867) awarded $3.4 billion across 3,275 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 137 | $139 million |
| The Leland Stanford Junior University | California | 87 | $96.5 million |
| The Regents of the University of California, San Francisco | California | 78 | $89.9 million |
| Duke University | North Carolina | 79 | $75.5 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 57 | $73.9 million |
Who has won Environmental Health grants before
From fiscal 2021 to 2025, Environmental Health (93.113) awarded $2.1 billion across 1,980 grant awards, an average of $1.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | 49 | $87.7 million |
| The Trustees of Columbia University in the City of New York | New York | 69 | $78.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 59 | $71.5 million |
| Emory University | Georgia | 57 | $67.2 million |
| University of Southern California | California | 40 | $58.9 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-ES-21-006 still open?
No. It closed on September 20, 2023.
Who can apply for CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)?
Closed September 20, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-ES-21-006?
NIH RePORTER lists 24 projects funded under RFA-ES-21-006 in fiscal 2022 to 2026, at 18 institutions. The most were at University of Alabama at Birmingham, Schepens Eye Research Institute, Saint Louis University.
Who has won Environmental Health grants before?
The largest recipients over five fiscal years were Icahn School of Medicine at Mount Sinai, The Trustees of Columbia University in the City of New York, University of North Carolina at Chapel Hill. The program made 1,980 awards worth $2.1 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)